Emerging markets | Market commentary Is Turkey the canary in the coalmine for emerging markets?

Can the situation in Turkey be categorized as idiosyncratic – or are Turkey’s problems the ‘canary in the coalmine’ ahead of wider EM contagion?

24 Aug 2018

Stronger USD, tighter financial conditions

The US dollar remains absolutely fundamental to EM prospects. Historically the relative performance of EM equities has demonstrated a strong statistical relationship with the US dollar on a trade weighted basis.

The principal reason is that the overwhelming majority of EM corporate debt is denominated in US dollars. But there are other factors too, not least the negative impact of a stronger dollar on global trade – particularly commodities – to which EM demand growth is highly exposed.

In our view recent US dollar strength primarily reflects that global growth has become increasingly desynchronized, with the sustained robustness of US demand standing in ever sharper contrast with the moderating growth profile of other major developed economies. The policy actions of major central banks are therefore likely to remain on similarly separate paths and we expect the US Federal Reserve to continue hiking rates, albeit gently, at a time when rate hikes and tighter conditions are still some time away for its major counterparts. Against this backdrop, it is not surprising that the trade-weighted dollar has continued to rise.

For EM countries with significant external funding requirements and large current account deficits this backdrop is clearly far from ideal. In addition to Turkey, we would highlight countries including Argentina, Colombia, South Africa and Malaysia.

But the critical point is that EM overall is in much better shape than during the 2013 Taper Tantrum when similar fears arose about the impact on EM assets of tightening US financial conditions. Clearly, EM central banks also have tools at their disposal in the form of higher rates to respond to currency

So what is the outlook for the US dollar given the somewhat self-sustaining vicious cycle of USD strength and EM stresses?

In our view, the critical factor is ex-US growth.

China’s recent stimulus measures should cushion the economy, but will take time.

Meanwhile, data in Europe and Japan have shown signs of stabilization after a weak second quarter – but are still notably weaker than the US.

In the short-term, a strong US dollar is likely to ensure higher volatility in EM assets. Nonetheless, we believe fears about a step change in global financial conditions are overdone. Yes, the Fed is tightening. But it is doing so very slowly, with great transparency and with data dependence. Crucially in our view, real policy rates are zero. Meanwhile, the Fed has been unwinding its balance sheet precisely as it said it would a year ago, and may now end the process earlier than expected. What is very clear however is that that the Fed will maintain a significantly larger residual balance sheet than it did prior to the onset of QE.

Outlook for trade as protectionism escalates

On the trade front, President Trump’s initiation of a process to implement tariffs from 10%–25% on USD 200bn worth of Chinese goods is a credible threat. With ‘America First’ playing well to the US electorate, it seems unlikely that the US-China trade tensions at the center of investors’ concerns will dissipate before the US midterm elections in November. Nonetheless, we are also keenly aware how quickly investor sentiment can shift in either direction.

At the time of writing, investor concerns about the impact of a protracted trade war between the US and China on Chinese growth and corporate profitability are high. Low level talks between the two sides are, in our view, a positive sign albeit a small one.

Away from US/China trade relations, we believe it is unlikely that the US will seek to repeal its trade agreement with Mexico and Canada, or that the US will impose additional tariffs on the European Union. On the negative side, EM export volume growth had already begun to slow down prior to the increase in trade tensions. In our view, the most likely source of this trend is China’s deleveraging and rebalancing process.

How do we expect Chinese economic growth to evolve from here?

After injecting significant stimulus into the economy after the Global Financial Crisis, China reined back fiscal and credit support for the economy. In 2015, China’s nominal GDP growth fell as low as it did in the 2008 crisis and 2000 recession before the country eased policy late that year and in early 2016. Of course, China is the world’s second largest economy, contributing somewhere between 25% to 30% of global GDP growth in recent years (World Bank).

It is integral to global supply chains and commodity prices, and the collapse in China’s nominal GDP growth amplified pressures across EM over this period. Now, China’s growth momentum is again cooling as authorities de-risk the financial sector and address pollution. This managed slowdown has been well communicated and is set to be gradual, having learned the lessons from the sharp downturn several years ago.

Moreover, China’s recent cuts to its reserve requirements signal a bias towards liquidity provision and careful focus on the downside risks to growth.

China’s leaders currently face a very delicate balancing act in improving the long-term quality of Chinese growth without precipitating a sharper-than expected short-term slowdown in demand in the process. But having experienced something of a ‘nominal hard landing’ in 2015, China’s more balanced approach to deleveraging should ease concerns that history is repeating itself.

The most recent hard data shows the effects of deleveraging and the clampdown on local government spending as China rebalances its economy. The unemployment rate has edged higher from 4.8% to 5.1% while fixed asset investment in China’s non-rural areas rose 5.5% in the January-July period from a year ago, the slowest rate since end-1999. This is not necessarily something to be overly concerned about given that it is uneconomic capital investment that China is seeking to avoid going forward. Retail sales have slowed marginally from 9% y/y to 8.8%, but the underlying rate remains robust. Data showing that the contribution of emerging and high value added industries rebounded strongly in July also strikes a more positive note about the success of China’s rebalancing.


In our view, it is an entirely logical response by investors to events in Turkey to look around at other EM countries with similar twin deficits and wonder who is next.

However, while the Turkey situation has thrust the vulnerabilities of specific EM economies under the spotlight, most EM countries have significantly better fundamentals than they had in spring 2013, prior to the Taper Tantrum.

While EM currency selloffs can lead to vicious circles even without an obvious fundamental catalyst, we do not see this happening this time.

Moreover it is worth remembering that the situation in Turkey has escalated because of the lack of an orthodox or independent policy framework with which to address the current crisis and the imbalances in the Turkish economy.
While there are political obstacles to overcome in a number of countries with similar profiles to Turkey, we do not see the rejection of economic orthodoxy as something likely to take hold across EM. In time, we believe investors will view events in Turkey as idiosyncratic.

EM assets are likely to remain volatile in the short-term but given valuation support and overall investor positioning, there is the scope for a sharp rebound should the dollar stabilize, China growth rebound or the combative trade rhetoric between the US and China evolve into something more conciliatory.

We would also point out that one of EM’s enduring attractions is the economic diversity within its broad universe. This heterogeneity offers the opportunity to add value across EM asset classes through skilled active management. And while there are clearly reasons to approach EM asset classes with some caution over tactical investment horizons, we do not see sufficiently strong arguments for long-term investors to abandon EM exposure given secular support from factors including attractive valuations, diversification benefits and structural demographic trends.

Erin Browne
Head of Asset Allocation

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.